The antidiabetic hormone glucagon-like peptide-1 induces formation of new elastic fibers in human cardiac fibroblasts after cross-Activation of IGF-IR

Endocrinology

Volumn 156, Issue 1, 2015, Pages 90-102

  Qa'Aty, Nour ^a,b   Wang, Yanting ^a   Wang, Andrew ^a   Mao, Shuai ^a   Vincent, Matthew ^a,b   Husain, Mansoor ^b,c,d   Hinek, Aleksander ^a,b,c  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; ELASTIN; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; SOMATOMEDIN C RECEPTOR; MESSENGER RNA;

APOPTOSIS; ARTICLE; CARDIAC FIBROBLAST; CELL PROLIFERATION; CONTROLLED STUDY; ELASTIC FIBER; EXTRACELLULAR MATRIX; FEMALE; FIBROBLAST; GENE EXPRESSION; HEART INFARCTION; HEART MUSCLE CELL; HUMAN; HUMAN CELL; MALE; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; UPREGULATION; AMINO ACID SEQUENCE; CYTOLOGY; ELASTIC TISSUE; GENE EXPRESSION REGULATION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HEART MUSCLE; METABOLISM; PHYSIOLOGY;

AMINO ACID SEQUENCE; APOPTOSIS; CELL PROLIFERATION; ELASTIC TISSUE; FEMALE; FIBROBLASTS; GENE EXPRESSION REGULATION; GLUCAGON-LIKE PEPTIDE 1; HUMANS; MALE; MYOCARDIUM; RECEPTOR, IGF TYPE 1; RNA, MESSENGER;

EID: 84919774926     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2014-1519     Document Type: Article

References (63)

1. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131-2157
2. Wei Y, Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett. 1995;358(3):219-224
3. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, andβ-cell function in type 2 diabetes: A parallel-group study. Lancet. 2002;359(9309):824-830
4. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M.Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4):229-234
5. Ye Y, Perez-Polo JR, Aguilar D, Birnbaum Y. The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury. Basic Res Cardiol. 2011;106(6):925-952
6. Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004; 109(8):962-965
7. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon- like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail. 2006;12(9):694-699
8. Nikolaidis LA, Doverspike A, Hentosz T, et al. Glucagon-like peptide- 1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines. J Pharmacol Exp Ther. 2005; 312(1):303-308
9. Nikolaidis LA, Elahi D, Hentosz T, et al. Recombinant glucagonlike peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation. 2004;110(8):955-961
10. Sonne DP, Engstrom T, Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept. 2008;146(1-3):243-249
11. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon- like peptide 1 can directly protect the heart against ischemia/ reperfusion injury. Diabetes. 2005;54(1):146-151
12. BoseAK,MocanuMM,CarrRD,YellonDM.Glucagonlike peptide-1 is protective against myocardial ischemia/reperfusion injury when given either asapreconditioningmimeticorat reperfusion inanisolated rat heart model. Cardiovasc Drugs Ther. 2005;19(1):9-11
13. Zhao T, Parikh P, Bhashyam S, et al. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther. 2006; 317(3):1106-1113
14. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 2008; 117(18):2340-2350
15. Noyan-Ashraf MH, Momen MA, Ban K, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes. 2009;58(4):975-983
16. Bornstein P, Sage EH. Matricellular proteins: Extracellular modulators of cell function. Curr Opin Cell Biol. 2002;14(5):608-616
17. Dall'Armellina E, Karamitsos TD, Neubauer S, Choudhury RP. CMR for characterization of the myocardium in acute coronary syndromes. Nat Rev Cardiol. 2010;7(11):624-636
18. Fan D, Takawale A, Lee J, Kassiri Z. Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease. Fibrogenesis Tissue Repair. 2012;5(1):15
19. Porter KE, Turner NA. Cardiac fibroblasts: At the heart of myocardial remodeling. Pharmacol Ther. 2009;123(2):255-278
20. Burchfield JS, Xie M, Hill JA. Pathological ventricular remodeling: mechanisms: part 1 of 2. Circulation. 2013;128(4):388-400
21. Barnett CP, Chitayat D, Bradley TJ, Wang Y, Hinek A. Dexamethasone normalizes aberrant elastic fiber production and collagen 1 secretion by Loeys-Dietz syndrome fibroblasts: A possible treatment? Eur J Hum Genet. 2011;19(6):624-633
22. Bunda S, Wang Y, Mitts TF, et al. Aldosterone stimulates elastogenesis in cardiac fibroblasts via mineralocorticoid receptor-independent action involving the consecutive activation of Gα13, c-Src, the insulin-like growth factor-I receptor, and phosphatidylinositol 3-kinase/Akt. J Biol Chem. 2009;284(24):16633-16647
23. Shi J, Wang A, Sen S, et al. Insulin induces production of new elastin in cultures of human aortic smooth muscle cells.AmJ Pathol. 2012; 180(2):715-726
24. Mao S, Wang Y, Zhang M, Hinek A. Phytoestrogen, tanshinone IIA diminishes collagen deposition and stimulates new elastogenesis in cultures of human cardiac fibroblasts. Exp Cell Res. 2014;323(1):189-197
25. Coles JG, Boscarino C, Takahashi M, et al. Cardioprotective stress response in the human fetal heart. J Thorac Cardiovasc Surg. 2005; 129(5):1128-1136
26. Bunda S, Liu P,WangY, Liu K, Hinek A. Aldosterone induces elastin production in cardiac fibroblasts through activation of insulin-like growth factor-I receptors in a mineralocorticoid receptor-independent manner. Am J Pathol. 2007;171(3):809-819
27. Hwang JY, Johnson PY, Braun KR, et al. Retrovirally mediated overexpression of glycosaminoglycan-deficient biglycan in arterial smooth muscle cells induces tropoelastin synthesis and elastic fiber formation in vitro and in neointimae after vascular injury. Am J Pathol. 2008;173(6):1919-1928
28. Panjwani N, Mulvihill EE, Longuet C, et al. GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice. Endocrinology. 2013;154(1):127-139
29. Sen S, Bunda S, Shi J, Wang A, Mitts TF, Hinek A. Retinoblastoma protein modulates the inverse relationship between cellular proliferation and elastogenesis. J Biol Chem. 2011;286(42):36580-36591
30. Sproul EP, Argraves WS.Acytokine axis regulates elastin formation and degradation. Matrix Biol. 2013;32(2):86-94
31. Vasilcanu D, Girnita A, Girnita L, Vasilcanu R, Axelson M, Larsson O. The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway. Oncogene. 2004;23(47):7854-7862
32. Bose AK, Mocanu MM, Carr RD, Yellon DM. Myocardial ischaemia- reperfusion injury is attenuated by intact glucagon like peptide- 1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway. Cardiovasc Drugs Ther. 2007;21(4):253-256
33. Dokken BB, La Bonte LR, Davis-Gorman G, Teachey MK, Seaver N, McDonagh PF. Glucagon-like peptide-1 (GLP-1), immediately prior to reperfusion, decreases neutrophil activation and reduces myocardial infarct size in rodents. Horm Metab Res. 2011;43(5):300-305
34. AuneSE,YehST,KuppusamyP,KuppusamyML,KhanM,AngelosMG. Sivelestat attenuates myocardial reperfusion injury during brief low flow postischemic infusion. Oxid Med Cell Longev. 2013:279847
35. Bidouard JP, Duval N, Kapui Z, Herbert JM, O'Connor SE, Janiak P. SSR69071, an elastase inhibitor, reduces myocardial infarct size following ischemia-reperfusion injury. Eur J Pharmacol. 2003; 461(1):49-52
36. Ohta K, Nakajima T, Cheah AY, et al. Elafin-overexpressing mice have improved cardiac function after myocardial infarction. Am J Physiol Heart Circ Physiol. 2004;287(1):H286-H292
37. Li SH, Sun Z, Guo L, et al. Elastin overexpression by cell-based gene therapy preserves matrix and prevents cardiac dilation. J Cell Mol Med. 2012;16(10):2429-2439
38. Mizuno T, Mickle DA, Kiani CG, Li RK. Overexpression of elastin fragments in infarcted myocardium attenuates scar expansion and heart dysfunction. Am J Physiol Heart Circ Physiol. 2005;288(6): H2819-H2827
39. Mizuno T, Yau TM, Weisel RD, Kiani CG, Li RK. Elastin stabilizes an infarct and preserves ventricular function. Circulation. 2005; 112(9 suppl):I81-I88
40. Ledo I, Wu M, Katchman S, et al. Glucocorticosteroids up-regulate human elastin gene promoter activity in transgenic mice. J Invest Dermatol. 1994;103(5):632-636
41. Conn KJ, Rich CB, Jensen DE, et al. Insulin-like growth factor-I regulates transcription of the elastin gene through a putative retinoblastomacontrol element.Arole forSp3acting as a repressor of elastin gene transcription. J Biol Chem. 1996;271(46):28853-28860
42. Kucich U, Rosenbloom JC, Abrams WR, Rosenbloom J. Transforming growth factor-β stabilizes elastin mRNA by a pathway requiring active Smads, protein kinase C-δ, and p38. Am J Respir Cell Mol Biol. 2002;26(2):183-188
43. Pierce RA, Joyce B, Officer S, et al. Retinoids increase lung elastin expression but fail to alter morphology or angiogenesis genes in premature ventilated baboons. Pediatr Res. 2007;61(6):703-709
44. Bunda S, Kaviani N, Hinek A. Fluctuations of intracellular iron modulate elastin production. J Biol Chem. 2005;280(3):2341-2351
45. Dupont J, Holzenberger M. Biology of insulin-like growth factors in development. Birth Defects Res C Embryo Today. 2003;69(4):257-271
46. Dupont J, Pierre A, Froment P, Moreau C. The insulin-like growth factor axis in cell cycle progression. Horm Metab Res. 2003;35 (11-12):740-750
47. Jiang Y, Chan JL, Zong CS, Wang LH. Effect of tyrosine mutations on the kinase activity and transforming potential of an oncogenic human insulin-like growth factor I receptor. J Biol Chem. 1996; 271(1):160-167
48. Peterson JE, Kulik G, Jelinek T, ReuterCW,Shannon JA, Weber MJ. Src phosphorylates the insulin-like growth factor type I receptor on the autophosphorylation sites. Requirement for transformation by src. J Biol Chem. 1996;271(49):31562-31571
49. Monji A, Mitsui T, Bando YK, Aoyama M, Shigeta T, Murohara T. Glucagon-like peptide-1 receptor activation reverses cardiac remodeling via normalizing cardiac steatosis and oxidative stress in type 2 diabetes. Am J Physiol Heart Circ Physiol. 2013;305(3):H295-H304
50. Picatoste B, Ramirez E, Caro-Vadillo A, et al. Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulindependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms. PLoS One. 2013;8(10):e78330
51. Cornu M, Yang JY, Jaccard E, Poussin C, Widmann C, Thorens B. Glucagon-like peptide-1 protects β-cells against apoptosis by increasing the activity of an IGF-2/IGF-1 receptor autocrine loop. Diabetes. 2009;58(8):1816-1825
52. Buteau J, Foisy S, Joly E, PrentkiM.Glucagon-like peptide 1 induces pancreatic β-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes. 2003;52(1):124-132
53. Abbas A, Imrie H, Viswambharan H, et al. The insulin-like growth factor-1 receptor is a negative regulator of nitric oxide bioavailability and insulin sensitivity in the endothelium. Diabetes. 2011;60(8): 2169-2178
54. Shu S, Li X, Yang Y, et al. Inhibitory effect of siRNA targeting IGF-1R on endometrial carcinoma. Int Immunopharmacol. 2011; 11(2):244-249
55. Buerke M, Murohara T, Skurk C, Nuss C, Tomaselli K, Lefer AM. Cardioprotective effect of insulin-like growth factor I in myocardial ischemia followed by reperfusion. Proc Natl Acad Sci USA. 1995; 92(17):8031-8035
56. Davani EY, Brumme Z, Singhera GK, Côté HC, Harrigan PR, Dorscheid DR. Insulin-like growth factor-1 protects ischemic murine myocardium from ischemia/reperfusion associated injury. Crit Care. 2003;7(6):R176-R183
57. Pi Y, Goldenthal MJ, Marin-Garcia J. Mitochondrial involvement in IGF-1 induced protection of cardiomyocytes against hypoxia/reoxygenation injury. Mol Cell Biochem. 2007;301(1-2):181-189
58. O'Sullivan JF, Leblond AL, Kelly G, et al. Potent long-term cardioprotective effects of single low-dose insulin-like growth factor-1 treatment postmyocardial infarction. Circ Cardiovasc Interv. 2011; 4(4):327-335
59. Chao W, Matsui T, Novikov MS, et al. Strategic advantages of insulin-like growth factor-I expression for cardioprotection. J Gene Med. 2003;5(4):277-286
60. Li Q, Li B, Wang X, et al. Overexpression of insulin-like growth factor-1 in mice protects from myocyte death after infarction, attenuating ventricular dilation, wall stress, and cardiac hypertrophy. J Clin Invest. 1997;100(8):1991-1999
61. Touvron M, Escoubet B, Mericskay M, et al. Locally expressed IGF1 propeptide improves mouse heart function in induced dilated cardiomyopathy by blocking myocardial fibrosis and SRF-dependent CTGF induction. Dis Model Mech. 2012;5(4):481-491
62. McMullen JR, Shioi T, Huang WY, et al. The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase(p110α) pathway. J Biol Chem. 2004;279(6): 4782-4793
63. He Q, Li X, Zhang Z, et al. Overexpression of IGF-IR in malignant clonal cells in bone marrow of myelodysplastic syndromes. Cancer Invest. 2010;28(10):983-988.